Entera Bio ENTX Stock
Entera Bio Price Chart
Entera Bio ENTX Financial and Trading Overview
| Entera Bio stock price | 1.76 USD |
| Previous Close | 1.64 USD |
| Open | 1.63 USD |
| Bid | 1.77 USD x 100 |
| Ask | 1.67 USD x 100 |
| Day's Range | 1.61 - 1.64 USD |
| 52 Week Range | 0.91 - 3.22 USD |
| Volume | 21.39K USD |
| Avg. Volume | 1.06M USD |
| Market Cap | 80.1M USD |
| Beta (5Y Monthly) | 1.433 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.26 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9 USD |
ENTX Valuation Measures
| Enterprise Value | 77.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.9545455 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | |
| Price/Book (mrq) | 7.09607 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.175 |
Trading Information
Entera Bio Stock Price History
| Beta (5Y Monthly) | 1.433 |
| 52-Week Change | -12.76% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 3.22 USD |
| 52 Week Low | 0.91 USD |
| 50-Day Moving Average | 1.35 USD |
| 200-Day Moving Average | 1.68 USD |
ENTX Share Statistics
| Avg. Volume (3 month) | 1.06M USD |
| Avg. Daily Volume (10-Days) | 264.19K USD |
| Shares Outstanding | 49.29M |
| Float | 40.37M |
| Short Ratio | 0.12 |
| % Held by Insiders | 23.10% |
| % Held by Institutions | 15.98% |
| Shares Short | 332.66K |
| Short % of Float | 0.77% |
| Short % of Shares Outstanding | 0.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -45.0090% |
| Return on Equity (ttm) | -82.33% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 0 USD |
| EBITDA | -12476000 USD |
| Net Income Avi to Common (ttm) | -12377000 USD |
| Diluted EPS (ttm) | -0.26 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 4.14M USD |
| Total Cash Per Share (mrq) | 0.08 USD |
| Total Debt (mrq) | 448K USD |
| Total Debt/Equity (mrq) | 4.19 USD |
| Current Ratio (mrq) | 7.927 |
| Book Value Per Share (mrq) | 0.229 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9056000 USD |
| Levered Free Cash Flow (ttm) | -4841625 USD |
Profile of Entera Bio
| Country | United States |
| State | N/A |
| City | Jerusalem |
| Address | Kiryat Hadassah Minrav Building |
| ZIP | 9112002 |
| Phone | 972 2 532 7151 |
| Website | https://enterabio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 20 |
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Q&A For Entera Bio Stock
What is a current ENTX stock price?
Entera Bio ENTX stock price today per share is 1.76 USD.
How to purchase Entera Bio stock?
You can buy ENTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Entera Bio?
The stock symbol or ticker of Entera Bio is ENTX.
Which industry does the Entera Bio company belong to?
The Entera Bio industry is Biotechnology.
How many shares does Entera Bio have in circulation?
The max supply of Entera Bio shares is 49.29M.
What is Entera Bio Price to Earnings Ratio (PE Ratio)?
Entera Bio PE Ratio is now.
What was Entera Bio earnings per share over the trailing 12 months (TTM)?
Entera Bio EPS is -0.26 USD over the trailing 12 months.
Which sector does the Entera Bio company belong to?
The Entera Bio sector is Healthcare.
Entera Bio ENTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26266.39 USD — |
+0.61
|
4.11B USD — | 26041.13 USD — | 26316.81 USD — | — - | 4.11B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
140.62 USD — |
+0.23
|
— — | 138.5 USD — | 141.42 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1250.79 USD — |
+0.77
|
— — | 1233.72 USD — | 1252.43 USD — | — - | — — |
- {{ link.label }} {{link}}